iBio develops and offers product applications of its iBioLaunch and iBioModulator platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.

Employee Rating

3.4More
TypePublic
HQNewark, US
Founded2008
Size (employees)43 (est)
Websiteibioinc.com
iBio was founded in 2008 and is headquartered in Newark, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

iBio Office Locations

iBio has an office in Newark
Newark, (HQ)
100 9 Innovation Way
Show all (1)
Report incorrect company information

iBio Financials and Metrics

iBio Revenue

iBio's revenue was reported to be $444 k in FY, 2018
USD

Revenue (FY, 2018)

444.0k

EBIT (FY, 2018)

(14.2m)

Market capitalization (4-Dec-2018)

14.2m

Closing stock price (4-Dec-2018)

0.8

Cash (30-Jun-2018)

15.9m
iBio's current market capitalization is $14.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

205.0k1.9m948.0k394.0k444.0k

Revenue growth, %

803%(49%)

General and administrative expense

5.0m7.7m10.6m10.7m

R&D expense

1.9m3.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

819.0k349.0k160.0k134.0k379.0k135.0k75.0k37.0k122.0k153.0k353.0k

General and administrative expense

949.0k1.1m951.0k1.1m1.2m1.4m1.7m2.4m2.5m2.4m2.8m2.5m2.6m7.7m

R&D expense

552.0k585.0k343.0k1.2m815.0k551.0k704.0k1.0m

Operating expense total

(240.0k)1.6m1.3m2.2m2.0m2.0m2.4m3.5m3.3m3.4m4.0m3.5m3.6m10.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.6m9.5m23.0m8.1m15.9m

Inventories

118.0k182.0k264.0k

Current Assets

3.9m10.1m23.9m8.6m16.3m

PP&E

6.0k13.0k25.6m25.6m25.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

3.4m5.7m4.3m3.5m8.1m8.4m6.7m21.9m20.1m16.3m12.4m5.9m7.3m3.4m

Current Assets

4.6m6.9m5.5m4.1m9.0m9.1m7.2m22.7m20.5m16.7m13.0m6.4m7.8m4.0m

PP&E

5.0k7.0k20.0k14.0k10.0k14.0k25.8m25.6m25.5m25.8m25.3m25.3m25.3m

Total Assets

7.3m9.6m8.2m6.7m11.4m11.4m9.4m50.7m48.1m44.2m40.7m33.4m34.8m31.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.7m)(6.6m)(10.7m)(16.1m)

Depreciation and Amortization

361.0k363.0k940.0k1.7m1.7m

Inventories

97.0k(64.0k)(82.0k)

Accounts Payable

56.0k806.0k(125.0k)(257.0k)49.0k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

379.0k(1.2m)(1.3m)(1.4m)(1.7m)(1.8m)(4.1m)(3.6m)

Depreciation and Amortization

88.0k176.0k89.0k92.0k184.0k537.0k412.0k826.0k1.3m423.0k848.0k1.3m

Accounts Payable

1.1m200.0k815.0k171.0k190.0k342.0k53.0k(255.0k)7.0k(78.0k)(163.0k)102.0k

Cash From Operating Activities

(911.0k)(2.2m)(570.0k)(1.1m)(2.8m)(5.2m)(2.3m)(5.8m)(9.4m)(3.0m)(6.6m)(10.1m)
USDY, 2018

Revenue/Employee

10.3k

Financial Leverage

2.7 x
Show all financial metrics

iBio Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

19
Show all operating metrics

iBio Revenue Breakdown

Embed Graph

iBio revenue breakdown by geographic segment: 100.0% from United States and 0.0% from Other

Report incorrect company information

iBio Blogs

iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsor…

iBio and CC-Pharming Hold First Design and Strategy Meeting

Texas Meeting Initiates Plan to Bring Economical, Plant-Derived Rituximab to China Market NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Ph…

iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance

NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that NYSE Regulation has accepted the Company’s plan to regain compliance with the Exchange’s continued listing standards set forth in Section 1003(a)(iii) of the NYSE American …

iBio Company Life and Culture

Report incorrect company information

iBio Frequently Asked Questions

  • When was iBio founded?

    iBio was founded in 2008.

  • How many employees does iBio have?

    iBio has 43 employees.

  • What is iBio revenue?

    Latest iBio annual revenue is $444 k.

  • What is iBio revenue per employee?

    Latest iBio revenue per employee is $10.3 k.

  • Who are iBio competitors?

    Competitors of iBio include Lexicon Pharmaceuticals, Oxford Genetics and Spring Bank Pharmaceuticals.

  • Where is iBio headquarters?

    iBio headquarters is located at 100 9 Innovation Way, Newark.

  • Where are iBio offices?

    iBio has an office in Newark.

  • How many offices does iBio have?

    iBio has 1 office.